Education
About Us
Working with TipRanks
Follow Us
ANI Pharmaceuticals Inc (ANIP)
NASDAQ:ANIP
Earnings Data
Report Date
May 08, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
1.59Last Year’s EPS
1.7Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call conveyed strong positive momentum: record 2025 financials, rapid Cortrophin Gel and generics growth, robust cash generation, and clear 2026 guidance with continued top- and bottom-line expansion. Management acknowledged margin pressure from product mix and higher royalty rates, elevated near-term SG&A to fund a 90-person gout expansion, and access-seasonality headwinds in Q1. However, the magnitude and number of positive operating and financial outcomes (substantial revenue and EBITDA growth, cash flow, and confident guidance) outweigh the challenges, which management presented as known, manageable, and tied to growth investments and temporary access/seasonal factors.Company Guidance
Record Financial Performance in 2025
Full year revenues of $883.4M, up 44% year-over-year; adjusted non-GAAP EBITDA of $229.8M, up 47% YoY; adjusted non-GAAP diluted EPS $7.89 vs $5.20 prior year.
Exceptional Cortrophin Gel Growth
Cortrophin Gel net revenue of $347.8M for 2025, up 76% YoY; Q4 Cortrophin revenue $111.4M, up 88% YoY; company expects Cortrophin to grow 55%–65% in 2026 to $540M–$575M.
Strong Generics Performance and Cadence
Generics revenue $384.1M for 2025, up 28% YoY; Q4 generics $100.8M, up 28% YoY; company maintains cadence of 10–15 launches annually supporting continued cash generation.
Meaningful Top-Line Q4 Momentum
Fourth quarter total revenues $247.1M, up 30% YoY; Q4 adjusted non-GAAP EBITDA $65.4M, up 31% YoY; Q4 adjusted non-GAAP diluted EPS $2.33 vs $1.63 prior year.
Strong Cash Generation and Liquidity
Year-end unrestricted cash $285.6M (up $140.7M YoY); full year cash flow from operations $185.2M, providing capital for reinvestment and M&A optionality.
Clear 2026 Guidance with Continued Growth
2026 guidance of $1.055B–$1.115B revenue (≈19%–26% YoY growth), adjusted EBITDA $275M–$290M (≈20%–26% YoY), and adjusted EPS $8.83–$9.34 (≈12%–18% YoY) reflects confident outlook.
Strategic Focus on Rare Disease Transformation
Company prioritizes transforming into a leading rare disease company: Cortrophin commercialization expansion, 90-person organization dedicated to acute gout flares, ongoing Phase IV (150-patient) study and continued R&D investment.
Product and Commercial Enhancements
Launched Cortrophin prefilled syringe (April prior year) supporting patient convenience and adoption; ophthalmology volumes over 2x year-ago in Q4, reflecting commercial traction across specialties.
Improved Payer Coverage for ILUVIEN Indication
All 7 Medicare Administrative Contractors updated policies to cover ILUVIEN for both CIU/NIUPS and DME indications; top commercial payers with ILUVIEN-specific policies updated to reflect both indications.
Reduced Net Leverage
As of Dec 31, 2025 principal debt $629.1M; gross leverage 2.7x and net leverage 1.5x of 2025 adjusted EBITDA, reflecting deleveraging progress and capacity for disciplined capital deployment.
ANIP Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ANIP Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 10, 2025 | $90.43 | $88.93 | -1.66% |
Aug 08, 2025 | $69.01 | $81.48 | +18.07% |
May 09, 2025 | $71.53 | $66.30 | -7.31% |
Feb 28, 2025 | $54.58 | $61.89 | +13.39% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does ANI Pharmaceuticals Inc (ANIP) report earnings?
ANI Pharmaceuticals Inc (ANIP) is schdueled to report earning on May 08, 2026, Before Open (Confirmed).
What is ANI Pharmaceuticals Inc (ANIP) earnings time?
ANI Pharmaceuticals Inc (ANIP) earnings time is at May 08, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ANIP EPS forecast?
ANIP EPS forecast for the fiscal quarter 2026 (Q1) is 1.59.